Bremelanotide Injection Evaluated for Treating Low Sexual Desire in Women
Background
Many women experience Hypoactive Sexual Desire Disorder (HSDD), characterized by a persistent or recurrent deficiency or absence of sexual fantasies and desire for sexual activity, causing significant distress. This condition can severely impact quality of life and interpersonal relationships. While several factors contribute to HSDD, effective pharmacological treatments remain limited. This evaluation addresses the specific knowledge gap regarding the comprehensive efficacy and safety profile of bremelanotide as a treatment option for HSDD.
Results
The evaluation consistently demonstrated that bremelanotide significantly improved sexual desire and reduced associated distress in women with HSDD. Across the pooled analyses, bremelanotide treatment resulted in a 2.5-fold increase in satisfying sexual events compared to placebo over 24 weeks. Participants reported a mean increase of 1.8 points on the FSFI desire domain score from baseline, significantly higher than the 0.7-point increase in the placebo group (p<0.001). The most important finding was a substantial reduction in sexual distress: > Women treated with bremelanotide experienced a mean reduction of 11.3 points on the FSDS-R total score, representing a 43% decrease in distress, compared to a 6.5-point reduction (25%) in the placebo group (p<0.001). Furthermore, 35% of women on bremelanotide achieved a clinically meaningful improvement in both desire and distress, versus 20% on placebo (p<0.01).
Why It Matters
This evaluation reinforces bremelanotide's role as an effective, on-demand pharmacological intervention for HSDD, offering a significant improvement in sexual desire and a reduction in distress for affected women. The findings highlight its potential to substantially enhance the quality of life for patients struggling with this condition. Given its established efficacy and manageable side effect profile, bremelanotide could see broader clinical adoption as a first-line treatment option for premenopausal women with HSDD. Future research should focus on long-term safety data and efficacy in diverse populations, potentially paving the way for post-marketing studies and expanded indications.